GBP1 and breast cancer: Significantly, treatment of a panel of breast cancer cell lines demonstrated that 50% of the cell lines (3/6) failed to induce the expression of GBP-1 upon IFN-γ treatment, indicating a defect in IFN-γ signaling [11].